STAT
OCTOBER 30, 2024
Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage list for over two years, with different doses being listed in shortage at various times. Continue to STAT+ to read the full story…
STAT
APRIL 23, 2025
To date, Lilly and its rival, Novo Nordisk, have filed dozens of suits against numerous companies involved in compounding versions of semaglutide and tirzepatide, the obesity and diabetes drugs known as GLP-1s. Those lawsuits alleged trademark infringement, false claims and unfair competition, but have so far yielded varying outcomes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
MAY 7, 2025
Food and Drug Administration over a decision last year to remove two Eli Lilly drugs — the Zepbound weight loss medicine and the Mounjaro diabetes treatment — from a shortages list kept by the agency. The move means that patients will no longer have access to cheaper versions from compounding pharmacies.
STAT
DECEMBER 19, 2024
The agency said it would give these compounders a grace period of 60 to 90 days before enforcing rules that would put a halt to their work, in an effort to avoid disruption for patients.
STAT
APRIL 25, 2025
Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug semaglutide, sold under the brand names Ozempic and Wegovy. Compounding pharmacies are legally allowed to make versions of branded treatments if the drugs are deemed to be in shortage by the FDA.
STAT
JANUARY 6, 2025
Food and Drug Administration seeking to block compounding pharmacies in the U.S. The latest attempt focuses on liraglutide, an older, once-daily injectable product sold as Victoza and Xultophy for diabetes and Saxenda for obesity. … Novo Nordisk filed another citizen’s petition with the U.S.
STAT
APRIL 29, 2025
The explosion of compounded GLP-1 offerings over the past two years is coming to an end, and many patients are left with no good options. Now, hundreds of thousands of patients are stuck navigating uncharted waters as companies they entrusted with their health pursue strategies that may disrupt their care or present risks.
Expert insights. Personalized for you.
348 
Let's personalize your content